Nuclear Receptor & In Vitro Toxicology Solutions™

Get all the latest news from INDIGO

  • This field is for validation purposes and should be left unchanged.
  • HOME
  • ABOUT
    • About
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
  • PRODUCTS
    • Assays
    • Ortholog Assays
    • Growth Factor Receptors
    • In Vitro Toxicology Platform
    • MDR1 / Human P-Glycoprotein
    • Gene Expression
    • NASH Nuclear Receptors For Research
    • Disease States
    • Live Cell Multiplex
    • Custom Assay Development
  • TECHNICAL
    • Nuclear Receptor Profiling & Panels
    • Assay Kit Platform & Formats
    • FAQ
    • Discovery Toxicology
    • upcyte® Hepatocytes
    • Technical Manuals & Product Listing
    • Safety Data Sheets
    • Product Policies
    • Terms & Conditions
    • Limited Use Disclosures
  • CONTACT US
    • Contact INDIGO
    • Request Information
    • Request a Quote
    • Employment
    • Distributors
  • RESOURCES
    • Blog
    • Nuclear Receptor Resource
    • Scientific Whitepapers from INDIGO
    • New Research Publications
    • Scientific Posters
    • INDIGO Press Releases
    • INDIGO in the News

Nuclear Receptor & In Vitro Toxicology Solutions™

Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • HOME
  • ABOUT
    • About
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
  • PRODUCTS
    • Assays
    • Ortholog Assays
    • Growth Factor Receptors
    • In Vitro Toxicology Platform
    • MDR1 / Human P-Glycoprotein
    • Gene Expression
    • NASH Nuclear Receptors For Research
    • Disease States
    • Live Cell Multiplex
    • Custom Assay Development
  • TECHNICAL
    • Nuclear Receptor Profiling & Panels
    • Assay Kit Platform & Formats
    • FAQ
    • Discovery Toxicology
    • upcyte® Hepatocytes
    • Technical Manuals & Product Listing
    • Safety Data Sheets
    • Product Policies
    • Terms & Conditions
    • Limited Use Disclosures
  • CONTACT US
    • Contact INDIGO
    • Request Information
    • Request a Quote
    • Employment
    • Distributors
  • RESOURCES
    • Blog
    • Nuclear Receptor Resource
    • Scientific Whitepapers from INDIGO
    • New Research Publications
    • Scientific Posters
    • INDIGO Press Releases
    • INDIGO in the News

Metadichol, A Novel ROR Gamma Inverse Agonist and Its Applications in Psoriasis

Print Friendly, PDF & Email

ABSTRACT

Psoriasis affects 3% of the population worldwide, and there is no known cure. Psoriasis is associated with an increased risk of psoriatic arthritis, lymphomas, cardiovascular disease, and Crohn’s disease. Psoriasis treatments today include steroid and vitamin D3 cream, ultraviolet light, and immune system suppressing medications such as methotrexate.

The T cells responsible for psoriasis are Th1 and Th l7 cells. IL-22, produced by Th17 cells, is crucial for the proliferation of keratinocytes. IL-22 with the help of IL-17 can induce the critical events of psoriasis. To maintain Th17 cells, IL-23 is required, and it is released from tumor necrosis factor-alpha (TNF-alpha) induced pathways. The pathophysiology of psoriasis involves RORC (retinoic acid receptor-related orphan nuclear receptor gamma) as a critical transcription factor for the development of Th17 cells. FDA has approved an antibody Secukinumab® targeting TNF-α for the treatment of psoriasis. Other FDA approved drugs are Tremfya® targeting IL23 for treatment of moderate to severe plaque psoriasis and Taltz® that blocks IL17 for treatment of plaque psoriasis.

Metadichol® a nanoformulation of long-chain lipid alcohols derived from food is a TNF-alpha inhibitor and also binds to Vitamin D receptor (VDR) that could have beneficial effects on Psoriasis. VDR modulates Th1-mediated inflammatory disease like psoriasis. We now present evidence that Metadichol is an inverse agonist of RORγt and AHR (Aryl Hydrocarbon Receptor) thus controlling Th17, IL17 and IL22. Being a TNF-alpha inhibitor, it can control IL23 thus blocking the significant pathways that exacerbate psoriasis. We present case studies of 7 patients afflicted with psoriasis and skin related conditions and how treatment with Metadichol resolved the underlying disease. Metadichol® has properties that allow its use as a safe nontoxic, toxic solution to combating the growing number of psoriasis cases.

To read the full article click HERE.

Date of publication: 23 November 2017; Journal of Clinical & Experimental Dermatology Research

Author information: Palayakotai R. Raghavan (1)

(1) Nanorx Inc, Chappaqua, NY, United States

Filed Under: New Publications Tagged With: AhR, inverse agonist, psoriasis, ROR, RORC, RORg, RORγ, TNF alpha, VDR, Vitamin D

INDIGO Biosciences - The right partner for all your discovery and toxicology needs.
Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Simply fill out this form and we'll be in touch!

Product Resources

  • Technical Manuals & Product Listing
    • Manuals & Listings: Other Kits
  • Assay Kit Platform & Formats
  • Request a Quote
  • Sample Study Report
  • Study Work Order Form
NRR - Nuclear Receptor Resource

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Home
  • Products
  • Request a Quote
  • FAQ

© 2020 INDIGO Biosciences, Inc. All Rights Reserved